Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tilli, Tatiana M ^a   Bellahcène, Akeila ^b   Castronovo, Vincent ^b   Gimba, Etel R P ^a,c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Angiogenesis; Gene expression; Osteopontin; PCR array; Splicing isoform

Indexed keywords

OSTEOPONTIN; OSTEOPONTIN C; UNCLASSIFIED DRUG; VASCULOTROPIN A; RNA ISOFORM; TRANSCRIPTOME;

ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE INTERACTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MOLECULAR PATHOLOGY; MULTIPLEX POLYMERASE CHAIN REACTION; OVARIAN CANCER CELL LINE; OVARY CANCER; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; VASCULOTROPIN A GENE; ALTERNATIVE RNA SPLICING; CELL MOTION; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; OVARY TUMOR; PROSTATE TUMOR; TUMOR CELL LINE;

ALTERNATIVE SPLICING; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MALE; OSTEOPONTIN; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; RNA ISOFORMS; TRANSCRIPTOME;

EID: 84902057680     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-433     Document Type: Article

References (63)

1. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011, 15:1113-1126. 10.1517/14728222.2011.594438, 21718227.
2. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal 2011, 5:111-122. 10.1007/s12079-011-0130-6, 3088790, 21516514.
3. Davidson B, Holth A, Moripen L, Trope' CG, Shih IM. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol 2011, 42:991-997. 10.1016/j.humpath.2010.10.013, 21315424.
4. Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012, 107:840-846. 10.1038/bjc.2012.345, 3425969, 22871886.
5. Gimba ER, Tilli TM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett 2013, 331:11-17. 10.1016/j.canlet.2012.12.003, 23246372.
6. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF, Gimba ER. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011, 9:280-293. 10.1158/1541-7786.MCR-10-0463, 21263033.
7. Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 2011, 92:13-19.
8. Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcène A, Castronovo V, Gimba ER. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012, 72:1688-1699. 10.1002/pros.22523, 22495819.
9. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six " hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog 2005, 43:225-236. 10.1002/mc.20105, 15864800.
10. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2756. 10.1172/JCI107470, 302542, 4355998.
11. Zhang W, Liu Y, Sun N, Wang D, Boyd-Kirkup J, Dou X, Han JD. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep 2013, 4:542-553. 10.1016/j.celrep.2013.07.010, 23933257.
12. Nishio T, Kawaguchi S, Yamamoto M, Iseda T, Kawasaki T, Hase T. Tenascin-C regulates proliferation and migration of cultured astrocytes in a scratch wound assay. Neuroscience 2005, 132:87-102. 10.1016/j.neuroscience.2004.12.028, 15780469.
13. Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 2012, doi:10.1002/14651858.CD008941.
14. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. clowes memorial award lecture. Cancer Res 1986, 46:467-473.
15. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, Muhr D, Wayne TL, Chu G, Davis RW, Wagner TM, Oefner PJ. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003, 63:3325-3333.
16. Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, Dohmae N, Kogure M, Kang D, Neal DE, Ponder BA, Yamaue H, Nakamura Y, Hamamoto R. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 2012, 14:476-486. 3394190, 22787429.
17. Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P, Mancuso S. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer 1998, 75:34-39. 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2, 9426687.
18. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Strömblad S, Cheung AN. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A 2010, 107:18622-18627. 10.1073/pnas.0907481107, 2972956, 20926745.
19. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010, 116:2621-2634.
20. Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B. Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol 2009, 30:15-25. 10.1159/000199447, 19194111.
21. Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C, D'Incalci M. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res 2000, 20:4835-4840.
22. Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X, Li Y. Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2010, 3:44. doi:10.1186/1756-8722-3-44, 10.1186/1756-8722-3-44, 2992472, 21080944.
23. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 2011, 17:6356-6366. 10.1158/1078-0432.CCR-11-0735, 3186862, 21849418.
24. Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer 2011, 104:1278-1287. 10.1038/bjc.2011.84, 3078595, 21487429.
25. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nuñez G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002, 62:924-931.
26. Zielinski RR, Eigl BJ, Chi KN. Targeting the apoptosis pathway in prostate cancer. Cancer J 2013, 19:79-89. 10.1097/PPO.0b013e3182801cf7, 23337761.
27. Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM, Fan S. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001, 488:179-184. 10.1016/S0014-5793(00)02430-3, 11163768.
28. Zhang H, Zhang Y, Duan HO, Kirley SD, Lin SX, McDougal WS, Xiao H, Wu CL. TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer 2008, 123:810-816. 10.1002/ijc.23638, 18528861.
29. Smith A, Karpova Y, D'Agostino R, Willingham M, Kulik G. Expression of the Bcl-2 Protein BAD promotes prostate cancer growth. PLoS One 2009, 4:e6224. doi:10.1371/journal.pone.0006224, 10.1371/journal.pone.0006224, 2704953, 19593445.
30. Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer. Genes Chromosomes Cancer 2012, 51:781-791. 10.1002/gcc.21963, 22505341.
31. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol 2009, 4:287-313. 10.1146/annurev.pathol.4.110807.092246, 2679364, 18842102.
32. Powers GL, Marker PC. Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med 2013, 5:243-256. 10.1002/wsbm.1208, 3583581, 23335485.
33. Okuyama H, Endo H, Akashika T, Kato K, Inoue M. Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 2010, 70:10213-10223. 10.1158/0008-5472.CAN-10-2720, 20980433.
34. Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K. C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 2008, 99:1269-1275. 10.1038/sj.bjc.6604650, 2570515, 18854825.
35. Zhang PN, Sun H. Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 2007, 42:196-200.
36. McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, Smyth JF, Langdon SP. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 2006, 27:729-739.
37. Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res 2002, 22:1993-1999.
38. Tang HJ, Jin X, Wang S, Yang D, Cao Y, Chen J, Gossett DR, Lin J. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol 2006, 100:308-317. 10.1016/j.ygyno.2005.08.044, 16209885.
39. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007, 67:9425-9434. 10.1158/0008-5472.CAN-07-1310, 2941899, 17909052.
40. Carbone G, Napoli S, Valentini A, Cavalli F, Watson D, Catapano C. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucl Acids Res 2004, 32:4358-4367. 10.1093/nar/gkh744, 514370, 15314206.
41. Song G, Ming Y, Mao Y, Bao S, Ouyang G. Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells. Exp Biol Med 2008, 233:1537-1545.
42. Tudoran O, Neagoe I, Balacescu O, Dronca E, Burz C, Balacescu L, Nedelea I, Irimie AL, Popescu O, Irimie F, Cristea V. Evaluation of tumor angiogenesis through VEGF modulation in ovarian cancer in vivo using RNA interference. Rom Biotechnol Lett 2009, 14:4560-4566.
43. Aragon-Ching J, Madan R, Dahut W. Angiogenesis inhibition in prostate cancer: current uses and future promise. J Oncol 2010, doi:10.1155/2010/361836.
44. May T, Yang J, Singh M, Welch W, Sugrue S, Berkowitz R, Ng S. Differential expression of the C-Terminal binding protein-2 highlight important protein pathways in ovarian carcinogenesis and suggest that its transcriptional function may be modulated by the novel nuclear protein Pinin. Cancer Res 2011, 71:2036.
45. Desgrosellier J, Cheresh D. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22. 10.1038/nrc2748, 20029421.
46. Apostolopoulos J, Sparrow RL, McLeod JL, Collier FM, Darcy PK, Slater HR, Ngu C, Gregorio-King CC, Kirkland MA. Identification and characterization of a novel family of mammalian ependymin-related proteins (MERPs) in hematopoietic, nonhematopoietic, and malignant tissues. DNA Cell Biol 2001, 20:625-635. 10.1089/104454901753340613, 11749721.
47. Versnel MA, Haarbrink M, Langerak AW, de Laat PA, Hagemeijer A, van der Kwast TH, van den Berg-Bakker LA, Schrier PI. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet 1994, 73:60-64. 10.1016/0165-4608(94)90183-X, 8174076.
48. Castillejo A, Mata-Balaguer T, Guarinos C, Castillejo MI, Martínez-Cantó A, Barberá VM, Montenegro P, Ochoa E, Lázaro R, Guillén-Ponce C, Carrato A, Soto JL. The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study. BMC Cancer 2009, 9:406. 10.1186/1471-2407-9-406, 2784798, 19930569.
49. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009, 119:3011-3023. 10.1172/JCI39065, 2752076, 19741298.
50. Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, Hodgkinson C, McVey R, Kitchener H, Jayson GC. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 2010, 10:495-504. 10.4161/cbt.10.5.12585, 3040972, 20595807.
51. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007, 26:6238-6243. 10.1038/sj.onc.1210429, 2753215, 17369840.
52. Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. J Clin Oncol 2012, 30:441-444. 10.1200/JCO.2011.38.7621, 22184396.
53. Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene 2014, 33:2295-2306. 10.1038/onc.2013.184, 23728342.
54. Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, Pu P, Kang C, Jiang T, Liu N, You Y. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 2011, 90:642-648. 10.1016/j.ejcb.2011.03.005, 21616556.
55. Blasberg J, Goparaju CM, Pass HI, Donington JS. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Sur 2010, 139:1587-1593.
56. Wang FQ, Fisher J, Fishman DA. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 2011, 120:247-255. 10.1016/j.ygyno.2010.10.032, 21093894.
57. Rao YM, Ji M, Chen CH, Shi HR. Effect of siRNA targeting MTA1 on metastasis malignant phenotype of ovarian cancer A2780 cells. J Huazhong Univ Sci Technolog Med Sci 2013, 33:266-271. 10.1007/s11596-013-1109-8, 23592142.
58. Ji Y, Zhang P, Lu Y, Ma D. Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. J Huazhong Univ Sci Technolog Med Sci 2006, 26:359-362. 10.1007/BF02829576, 16961294.
59. Klein R, Bernstein D, Higgins S, Higgins C, Higgins P. SERPINE1 expression discriminates site-specific metastasis in human melanoma. Exp Dermatol 2012, 21:551-554. 10.1111/j.1600-0625.2012.01523.x, 3383094, 22716255.
60. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001, 7:2396-2404.
61. Zhang J, Sud S, Mizutani K, Gyetko M, Pienta K. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011, 13:23-30. 3022425, 21245937.
62. Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest 2011, 40:447-464. 10.3109/08820139.2011.557795, 21391788.
63. Pulukuri SM, Rao JS. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol 2008, 32:757-765. 2292413, 18360703.